Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
2상
조기 종료
NCT05167409
| 대상 질환 | Microsatellite Stable Metastatic Colorectal Cancer |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | University of Colorado, Denver |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 19 명 |
|---|
| 중재(약물) | Evorpacept (ALX148), Cetuximab, Pembrolizumab |
|---|
| 시작일 | 2022년 7월 28일 |
|---|
| 완료일 | 2024년 10월 30일 |
|---|
| 결과 공개일 | 2026년 7월 22일 |
|---|
요약
This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Objective Response Rate (ORR)
The duration of time during which tumor assessments were performed for each individual patient. Per protocol, assessments will continue until disease progression. The latest assessment was performed at Cycle 21, Day 15 (14.5 mo after informed consent) · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 1 Participants |
|---|
Determine the Recommended Dose (RD) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab
During the safety run-in, each patient must have completed at least the 1st cycle (3 weeks) of treatment. · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 1 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 0 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.